Breaking News Instant updates and real-time market news.

JCP

J.C. Penney

$3.31

-0.23 (-6.50%)

, CELG

Celgene

$100.83

-2.29 (-2.22%)

07:30
12/01/17
12/01
07:30
12/01/17
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Thursday in J C Penney (JCP), Celgene (CELG), Sprint (S), Best Buy (BBY), Lam Research (LRCX), and GNC Holdings (GNC).

JCP

J.C. Penney

$3.31

-0.23 (-6.50%)

CELG

Celgene

$100.83

-2.29 (-2.22%)

S

Sprint

$5.99

-0.08 (-1.32%)

BBY

Best Buy

$59.61

0.78 (1.33%)

LRCX

Lam Research

$192.33

-2.31 (-1.19%)

GNC

GNC Holdings

$5.58

-0.49 (-8.07%)

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 18

    Jan

  • 25

    Mar

JCP J.C. Penney
$3.31

-0.23 (-6.50%)

11/13/17
SBSH
11/13/17
NO CHANGE
Target $1.5
SBSH
Sell
J.C. Penney quarter raises several concerns, says Citi
Although the better than expected sales in J.C. Penney's Q3 led to a short squeeze, the quarter raised several concerns, Citi analyst Paul Lejuez tells investors in a post-earnings research note. Transactions were still down even with all the promotions and higher penetration of credit in appliances is a risk, the analyst contends. Further, he believes the comp boost from appliances is likely to slow meaningfully in Q4. Lejuez continues to believe Penny's "high amount of debt on the business leaves little value left for equity holders." He keeps a Sell rating on the shares with a $1.50 price target.
11/30/17
COWN
11/30/17
NO CHANGE
Target $4
COWN
Market Perform
J.C. Penney taking steps toward a comeback, says Cowen
Cowen analyst Oliver Chen met with J.C. Penney and said he is confident the company's liquidity, its multi-year ability to drive free cash flow, and controlled capital expenditures will mitigate some risk. He likes management's simplification of marketing, its value messaging and execution, and leveraging of non-apparel categories, which should drive greater consistency in traffic and growth. Chen maintains his Market Perform rating and $4 price target on J.C. Penney shares as he looks for visibility on greater consistency in traffic trends.
10/30/17
10/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. 2. Merck (MRK) downgraded to Hold from Buy at SunTrust and to Equal Weight from Overweight at Morgan Stanley, as well as Barclays. 3. J.C. Penney (JCP) downgraded to Sell from Neutral at Citi, to Neutral from Buy at Northcoast, and to Neutral from Positive at Susquehanna. 4. Macy's (M) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying the retailer's sales and margins have been pressured for several years, and J.C. Penney's weak third quarter preannouncement on Friday serves as reminder of just how challenging the department store space is. 5. Under Armour (UAA, UA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes saying he expects management to lower fourth quarter guidance on its Q3 conference call due to the highly promotional environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/17
NRCS
10/30/17
DOWNGRADE
NRCS
Neutral
J.C. Penney downgraded to Neutral from Buy at Northcoast
CELG Celgene
$100.83

-2.29 (-2.22%)

11/20/17
JEFF
11/20/17
NO CHANGE
Target $125
JEFF
Buy
Celgene shares can rebound to $125 in 12-18 months, says Jefferies
After hosting investor meetings with management, Jefferies analyst Michael Yee is more positive on his view that Celgene (CELG) shares can rebound to $125 over the next 12-18 months. The biotech closed Friday up 75c to $104.10. The company could generate "a conservative" $50B in free cash flow in the next five year even before Revlimid starts eroding in 2022, Yee tells investors in a research note. As such, management "can easily deploy the balance sheet" and bring in one or a few late-stage assets to diversify and ease investor concerns, the analyst adds. Yee thinks PARP inhibitors like Clovis Oncology (CLVS) "fit that mold and that's a good first step." The analyst has a Buy rating on Celgene with a $125 price target.
11/01/17
CANT
11/01/17
NO CHANGE
Target $58
CANT
Neutral
Cantor ups bluebird target to $58, maintains Underweight rating
Cantor Fitzgerald analyst Elemer Piros raised his price target for bluebird bio (BLUE) to $58 from $39 following the introduction of multiple myeloma into his model. While no new data were introduced, partner Celgene (CELG) is planning to move the program to the pivotal setting, Piros tells investors in a research note. The analyst, however, remains "only cautiously optimistic" of the company's eventual success in sickle cell disease. The American Society of Hematology abstracts today provided an early glimpse at the modified drug manufacturing process for sickle cell disease, the analyst notes.
10/30/17
FBCO
10/30/17
NO CHANGE
Target $128
FBCO
Outperform
Celgene ozanimod data 'solid,' expectations high on safety, says Credit Suisse
Credit Suisse analyst Alethia Young says that while ozanimod full data was "very strong," Celgene set the expectations high for the full data and so she does not expect the stock to move on this data. The analyst sees increased importance for ozanimod's success to help diversify the portfolio beyond Revlimid. Young reiterates an Outperform rating and $128 price target on the shares.
10/30/17
OPCO
10/30/17
NO CHANGE
Target $166
OPCO
Outperform
Oppenheimer raises Celgene target to $168 on 'highly positive' study
Oppenheimer analyst Leah Rush Cann raised her price 12- to 18-month price target for shares of Celgene (CELG) to $168 from $163 citing the "highly positive" Radiance trial results. The stock in midday trading is up 2% to $100.00. The study, evaluating the efficacy and safety of Ozanimod versus a first-line treatment, Biogen's (BIIB) Avonex, in patients with relapsing multiple sclerosis met primary and secondary endpoints with "highly positive and significant results," and serious adverse events were reported to be low and similar across all treatment arms, Cann tells investors in a research note. The analyst is now including "modest" estimated sales of Ozanimod in multiple sclerosis starting in 2019. She keeps an Outperform rating on Celgene.
S Sprint
$5.99

-0.08 (-1.32%)

11/09/17
ARGS
11/09/17
NO CHANGE
Target $170
ARGS
Buy
American Tower price target raised to $170 from $150 at Argus
Argus analyst Jacob Kilstein raised his price target on American Tower to $170 and kept his Buy rating. Kilstein says the company stands out among tower operators based on its margins, FFO growth rates, and high-quality assets, while also noting its international expansion steps. Additionally, the analyst says that the company stands to benefit from receding risks of telecom industry consolidation, as evidenced by the 6% jump in stock price when Sprint (S) and T-Mobile (TMUS) announced an end of their merger talks.
11/06/17
11/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Weatherford (WFT) downgraded to Neutral from Buy at Citi with analyst Scott Gruber saying the company's turnaround is going to take time and the ending remains uncertain. 2. Hyatt (H) downgraded to Neutral from Buy at B. Riley FBR with analyst Bryan Maher citing valuation following the stock's recent rally. 3. Sprint (S) downgraded to Underweight from Sector Weight at KeyBanc with analyst Brandon Nispel saying competitive intensity in the wireless industry will likely increase now that the company could not reach a merger agreement with T-Mobile (TMUS). 4. Goldman Sachs (GS) downgraded to Sell from Hold at Vertical Group with analyst Richard Bove saying "more earnings issues may surface" as the company continues to pursue its traditional business model when it is evident it is no longer relevant. 5. Hilton (HLT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jeffrey Donnelly citing the stock's "premium valuation" and a lack of visible catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/17
KEYB
11/27/17
NO CHANGE
Target $177
KEYB
Overweight
American Tower price target raised to $177 from $156 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for American Tower (AMT) to $177 from $156 and raised his 2018 U.S. new leasing activity to reflect potential activity from Sprint (S). The analyst reiterates an Overweight rating on American Tower's shares.
11/27/17
KEYB
11/27/17
NO CHANGE
Target $192
KEYB
Overweight
SBA Communications price target raised to $192 from $179 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for SBA Communications (SBAC) to $192 from $179 to reflect potential contribution from Sprint (S) as well as his belief that FirstNet could also be a contributor in 2019. The analyst reiterates an Overweight rating on SBA Communications' shares.
BBY Best Buy
$59.61

0.78 (1.33%)

11/16/17
BOFA
11/16/17
NO CHANGE
Target $64
BOFA
Buy
Best Buy underlying performance remains solid, says BofA/Merrill
BofA/Merrill said Best Buy reported results slightly below expectations, but they were impacted by recent hurricanes and a shift in iPhone demand to Q4. The firm's analyst said underlying performance remains solid and believes the company is well positioned for the Holiday given a solid product cycle, investments in delivery and increased speed, and market share gains. The firm rates shares a Buy with a $64 price target, down from $68.
11/27/17
KEYB
11/27/17
NO CHANGE
KEYB
Rapid erosion in physical stores may be abating, says KeyBanc
KeyBanc's research consumer team says that while online remains the key avenue for growth, the rapid erosion in physical store sales may be abating. The analyst noted that strong store checks reinforce their thesis that apparel is back, with the strongest traffic at Urban Outfitters (URBN) and lululemon (LULU). Meanwhile, Wal-Mart (WMT) was able to eschew wrist bands and had solid inventory of doorbusters, while Gap (GPS) saw strong traffic at Old Navy, they contend. Additionally, KeyBanc's team says its channel checks suggest Best Buy (BBY) continues to gain share and drove healthy traffic, while Bed Bath & Beyond (BBBY) offered slightly more aggressive, but still uninspiring, undifferentiated promotions. Moreover, they believe Conn's (CONN) maintains momentum with its credit offering, credit improvement story, and the recovery in the Hurricane Harvey impacted markets. Checks also revealed solid Beauty positioning, with Ulta Beauty (ULTA) as a winner with strong holiday positioning and good traffic on Thursday/Friday, the analysts added.
11/29/17
WEDB
11/29/17
NO CHANGE
Target $32
WEDB
Underperform
Amazon allows deeper TV discounting at Best Buy, says Wedbush
Wedbush analyst Michael Pachter notes that online checks suggest that Best Buy (BBY) undercut Amazon (AMZN) on TV pricing throughout the Thanksgiving Holiday period, with deals continuing at Best Buy after Cyber Monday, while Amazon surprised him by raising prices. Additionally, the analyst believes Best Buy's Q4 comps guidance is more realistic, due to "Amazon's mercy." He reiterates an Underperform rating and $32 price target on Best Buy's shares.
11/16/17
DBAB
11/16/17
NO CHANGE
Target $56
DBAB
Hold
Best Buy price target lowered to $56 from $58 at Deutsche Bank
Deutsche Bank analyst Mike Baker does not expect consensus estimates for Best Buy to increase following today's Q3 results. In fact, some analysts may take numbers down a bit, Baker tells investors in a post-earnings research note titled "BBY Good, But Not Great." He notes the outlook for Q4 is in line on comps and below consensus on earnings. After the strong rally year-to-date, the analyst thinks the shares could give back some of the gains. Baker lowered his price target for Best Buy shares to $56 from $58 and keeps a Hold rating on the name.
LRCX Lam Research
$192.33

-2.31 (-1.19%)

11/15/17
RBCM
11/15/17
NO CHANGE
Target $225
RBCM
Outperform
Lam Research price target raised to $225 from $210 at RBC Capital
RBC Capital analyst Amit Daryanani raised his price target on Lam Research to $225 after the company announced a $2B stock buyback and raised its dividend 11%. Daryanani says the timing of the new capital return program is in line with the past relative to the analyst day schedule and is also a net positive from an "outlook standpoint", boosting investor confidence in a sustained wafer fabrication equipment environment. Daryanani keeps his Outperform rating on Lam Research, saying it will benefit as the "arms dealer" in the memory race.
10/18/17
COWN
10/18/17
NO CHANGE
Target $32
COWN
Market Perform
Ultra Clean should have a very strong year, says Cowen
Cowen analyst Karl Ackerman said the strong commentary out of Lam Research (LRCX) and Applied Materials (AMAT) suggests this should be a very strong year for Ultra Clean (UCTT). He said the company sits in a unique position within the OLED supply chain, which is in the midst of a technology transition. Ackerman maintained his Market Perform rating and raised his price target to $32 from $28 on Ultra Clean shares.
11/15/17
DBAB
11/15/17
NO CHANGE
Target $230
DBAB
Buy
Lam Research price target raised to $230 from $220 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for Lam Research to $230 after the company announced a $2B share repurchase authorization and 11% dividend increase. The analyst says Lam's ability to raise capital returns is one of the key pillars of his Buy thesis.
10/18/17
NEED
10/18/17
NO CHANGE
Target $235
NEED
Buy
Lam Research price target raised to $235 from $220 at Needham
Needham analyst Y. Edwin Mok raised his price target on Lam Research to $235 and maintained his Buy rating following earnings, noting that management comments helped to soothe concerns over a near term peak. Mok says the company will continue to leverage is exposure to memory and will also benefit from progress in penetrating foundry/logic applications, as the Q3 shipments in that space rose to 34% from 27% of the total last quarter.
GNC GNC Holdings
$5.58

-0.49 (-8.07%)

01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell from Neutral at Goldman
01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell on brand re-launch, competition at Goldman
As previously reported, Goldman downgraded GNC Holdings to Sell from Neutral and lowered its price target to $8 from $12. Analyst Stephen Tanal believes GNC's brand re-launch, which it cut prices meaningfully across half of its assortment and ended its Gold Card loyalty program, will weigh on profitability to a much greater degree than consensus estimates reflect. The analyst expects persistent same-store-sales declines to persist given share losses to conventional retailers including grocers, drug stores, warehouse/clubs, as well as online challengers.
02/15/17
MACQ
02/15/17
NO CHANGE
Target $20
MACQ
Outperform
GNC Holdings shares pricing in 'draconian' outcomes, says Macquarie
Macquarie analyst Bob Summers said GNC Holdings' Q4 and near-term results will prove challenging but management has made decisions that will significantly increase the company's long-term potential to succeed by simplifying pricing and having consistent in-store and online pricing. The analyst said these efforts will pressure margins, but shares are pricing in "draconian" outcomes with shares trading at just over 4x P/E. Summers expects free cash flow to remain positive, which could be further enhanced by cutting the dividend and notes there are no near-term debt maturities to create credit risk. The analyst said even a "slight bend" in same-store sales trends could produce a dramatic positive outcome and reiterates his Outperform rating and $20 price target on GNC Holdings.
04/19/17
JPMS
04/19/17
NO CHANGE
Target $12
JPMS
Neutral
GNC Holdings price target raised to $12 from $10 at JPMorgan
JPMorgan analyst Christopher Horvers raised his price target for GNC Holdings to $12 saying yesterday's earnings and comp beat "take off the table the terminal value question that many investors were focused on." The question, however, is if the traffic is sustainable and whether GNC can turn the decline in average ticket up, Horvers tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

OIS

Oil States

$24.68

1.275 (5.45%)

11:52
12/13/17
12/13
11:52
12/13/17
11:52
Recommendations
Oil States analyst commentary  »

Oil States target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BURL

Burlington Stores

$110.92

1.3 (1.19%)

11:50
12/13/17
12/13
11:50
12/13/17
11:50
Options
Burlington draws a bullish option play as shares see strength »

Burlington draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BT

BT Group

$18.04

-0.0501 (-0.28%)

11:49
12/13/17
12/13
11:49
12/13/17
11:49
Upgrade
BT Group rating change  »

BT Group upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHT

Universal Health Realty

$75.28

1.705 (2.32%)

11:45
12/13/17
12/13
11:45
12/13/17
11:45
Conference/Events
Universal Health Realty management to meet with Jefferies »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:40
12/13/17
12/13
11:40
12/13/17
11:40
General news
Bund/T-note spread widening remains intact »

Bund/T-note spread…

CERN

Cerner

$70.36

0.23 (0.33%)

11:39
12/13/17
12/13
11:39
12/13/17
11:39
Periodicals
VA Secretary says contract with Cerner held up by questions, Politico reports »

Veterans Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:34
12/13/17
12/13
11:34
12/13/17
11:34
Hot Stocks
PlainSite says Credit Acceptance disclosures belie 'deeply flawed' model »

In a "Reality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$287.83

-2.67 (-0.92%)

11:33
12/13/17
12/13
11:33
12/13/17
11:33
Conference/Events
CoStar Group management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

ROG

Rogers Corporation

$158.59

1.4 (0.89%)

11:30
12/13/17
12/13
11:30
12/13/17
11:30
Conference/Events
Rogers Corporation management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

11:30
12/13/17
12/13
11:30
12/13/17
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ROG

Rogers Corporation

$158.89

1.7 (1.08%)

11:29
12/13/17
12/13
11:29
12/13/17
11:29
Conference/Events
Rogers Corporation management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

HDP

Hortonworks

$19.76

0.18 (0.92%)

11:25
12/13/17
12/13
11:25
12/13/17
11:25
Conference/Events
Hortonworks management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 26

    Feb

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:20
12/13/17
12/13
11:20
12/13/17
11:20
Hot Stocks
Credit Acceptance moves lower following short report from PlainSite »

Shares of Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
12/13/17
12/13
11:17
12/13/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
12/13/17
12/13
11:16
12/13/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$96.15

-3.99 (-3.98%)

11:13
12/13/17
12/13
11:13
12/13/17
11:13
Hot Stocks
Ralph Lauren falls after Bofa/Merrill downgrade cites 'dimming' margin story »

Shares of Ralph Lauren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.58

0.555 (0.91%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Target: Shipt to continue to run business independently post-acquisition »

Shipt will be a wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.48

0.41 (0.65%)

, T

AT&T

$37.75

-0.35 (-0.92%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Cable, telecom stocks dip as T-Mobile plans to bring 'un-carrier' to TV »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$63.48

0.41 (0.65%)

T

AT&T

$37.75

-0.35 (-0.92%)

ROKU

Roku

$46.95

-1.03 (-2.15%)

CMCSA

Comcast

$39.51

1.07 (2.78%)

CMCSK

Comcast

CHTR

Charter

$329.99

-1.5 (-0.45%)

VZ

Verizon

$52.82

-0.375 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

LITE

Lumentum

$51.75

-1.75 (-3.27%)

, FNSR

Finisar

$19.30

-0.51 (-2.57%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Recommendations
Lumentum, Finisar, Apple analyst commentary  »

Apple's investment…

LITE

Lumentum

$51.75

-1.75 (-3.27%)

FNSR

Finisar

$19.30

-0.51 (-2.57%)

AAPL

Apple

$171.70

-0.97 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.73

-0.49 (-0.26%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Periodicals
Netflix executive fired over Masterson assault comments, Page Six says »

Netflix director of kids…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.64

0.62 (1.02%)

11:06
12/13/17
12/13
11:06
12/13/17
11:06
Technical Analysis
Technical View: Target spikes after acquiring Shipt for $550M »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.70

0.68 (1.11%)

11:02
12/13/17
12/13
11:02
12/13/17
11:02
Hot Stocks
Breaking Hot Stocks news story on Target »

Target to bring same-day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.69

0.67 (1.10%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Breaking Hot Stocks news story on Target »

Target: Same-day delivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.72

0.71 (1.16%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Target to buy same-day delivery platform Shipt for $550M in cash »

Target announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYI

Acuity Brands

$165.44

-8.79 (-5.05%)

10:59
12/13/17
12/13
10:59
12/13/17
10:59
Technical Analysis
Technical View: Acuity Brands tumbles, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 09

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.